Carnitine metabolism is thought to be negatively correlated with the progression of
hepatocellular carcinoma (HCC) and the specific molecular mechanism is yet to be fully elucidated. Here, we report that little characterized
cysteine-rich
protein 1 (CRIP1) is upregulated in HCC and associated with poor prognosis. Moreover, CRIP1 promoted HCC
cancer stem-like properties by downregulating
carnitine energy metabolism. Mechanistically, CRIP1 interacted with BBOX1 and the
E3 ligase STUB1, promoting BBOX1 ubiquitination and proteasomal degradation, and leading to the downregulation of
carnitine. BBOX1 ubiquitination at
lysine 240 is required for CRIP1-mediated control of
carnitine metabolism and
cancer stem-like properties. Further, our data showed that
acetylcarnitine downregulation in CRIP1-overexpressing cells decreased
beta-catenin acetylation and promoted nuclear accumulation of
beta-catenin, thus facilitating
cancer stem-like properties. Clinically, patients with higher CRIP1
protein levels had lower BBOX1 levels but higher nuclear
beta-catenin levels in HCC tissues. Together, our findings identify CRIP1 as novel upstream control factor for
carnitine metabolism and
cancer stem-like properties, suggesting targeting of the CRIP1/BBOX1/β-
catenin axis as a promising strategy for HCC treatment.